Scientists_NN
have_VPRT [PEAS]
developed_VBN
a_DT
blood_NN
test_NN
that_TSUB
can_POMD
predict_VB [PUBV]
whether_IN [WHCL]
people_NN
with_PIN
depression_NN
will_PRMD
respond_VB
to_PIN
common_JJ
antidepressants_NN
,_,
a_DT
discovery_NN
that_TSUB
could_POMD
bring_VB
in_PIN
a_DT
new_JJ
era_NN
of_PIN
personalised_JJ
treatment_NOMZ
for_PIN
people_NN
with_PIN
the_DT
debilitating_VBG
mental_JJ
illness_NOMZ
._.
Guided_VBN [PASTP]
by_PIN
this_DEMO
test_NN
,_,
the_DT
researchers_NN
said_VBD [PUBV]
,_,
doctors_NN
should_NEMD
in_PIN
future_JJ
be_VB [BEMA]
able_PRED
to_TO
direct_VB
depressed_JJ
patients_NN
with_PIN
a_DT
certain_JJ
level_NN
of_PIN
inflammation_NOMZ
in_PIN
their_TPP3
blood_NN
towards_PIN
earlier_TIME
treatment_NOMZ
with_PIN
a_DT
more_EMPH
potent_JJ
course_NN
of_PIN
antidepressants_NN
,_,
possibly_RB
including_VBG
combining_VBG
two_CD
medications_NOMZ
,_,
before_IN
they_TPP3
get_VPRT
worse_JJ
._.
``_``
This_DEMO
study_NN
moves_VPRT [SUAV]
us_FPP1
a_DT
step_NN
closer_RB
to_TO
providing_VBG
personalised_JJ
antidepressant_JJ
treatment_NOMZ
at_PIN
the_DT
earliest_JJ
signs_NN
of_PIN
depression_NN
,_,
''_''
said_VBD [PUBV]
Annamaria_NN
Cattaneo_NN
,_,
who_WP
led_VBD
the_DT
work_NN
at_PIN
King_NN
's_POS
College_NN
London_NN
's_POS
Institute_NN
of_PIN
Psychiatry_NN
,_,
Psychology_NN
&_CC
Neuroscience_NN
-LRB-_-LRB-
IoPPN_NN
-RRB-_-RRB-
._.
Depression_NN
is_VPRT [BEMA]
one_CD
of_PIN
the_DT
most_EMPH
common_JJ
forms_NN
of_PIN
mental_JJ
illness_NOMZ
,_,
affecting_VBG
more_EMPH
than_PIN
350_CD
million_CD
people_NN
worldwide_JJ
._.
It_PIT
is_VPRT [BYPA]
ranked_VBN
by_PIN
the_DT
World_NN
Health_NN
Organisation_NOMZ
-LRB-_-LRB-
WHO_WP
-RRB-_-RRB-
as_IN
the_DT
leading_VBG
cause_NN
of_PIN
disability_NOMZ
globally_RB
._.
Treatment_NOMZ
usually_RB
involves_VPRT
either_CC
medication_NOMZ
,_,
some_QUAN
form_NN
of_PIN
psychotherapy_JJ
,_,
or_CC
a_DT
combination_NOMZ
of_PIN
both_DT
._.
But_CC
around_PLACE
half_DT
of_PIN
all_QUAN
people_NN
treated_VBN [WZPAST]
for_PIN
depression_NN
fail_VPRT
to_TO
get_VB
better_JJ
with_PIN
first-line_JJ
antidepressants_NN
,_,
and_ANDC
around_PLACE
a_DT
third_JJ
of_PIN
patients_NN
are_VPRT [BEMA]
resistant_PRED
to_PIN
all_QUAN
available_JJ
medications_NOMZ
designed_VBN
to_TO
help_VB
._.
Until_IN
now_TIME
,_,
doctors_NN
have_VPRT [PEAS]
not_XX0
been_VBN [BEMA]
able_PRED
to_TO
establish_VB [PRIV]
whether_IN [WHCL]
someone_QUPR
will_PRMD
respond_VB
to_PIN
an_DT
antidepressant_JJ
,_,
or_CC
whether_IN
they_TPP3
might_POMD
need_VB
a_DT
more_EMPH
aggressive_JJ
treatment_NOMZ
plan_NN
from_PIN
the_DT
start_NN
._.
As_CONJ
a_NULL
result_NULL
,_,
patients_NN
are_VPRT [SPAU] [PASS]
often_RB
treated_VBN
with_PIN
a_DT
trial-and-error_JJ
approach_NN
,_,
trying_VBG [PRESP]
one_CD
drug_NN
after_IN
another_DT
for_PIN
months_NN
on_PIN
end_NN
and_CC
often_RB
seeing_VBG [PRIV]
no_SYNE
improvement_NOMZ
in_PIN
their_TPP3
symptoms_NN
._.
In_PIN
this_DEMO
study_NN
,_,
published_VBN [PASTP]
on_PIN
Tuesday_NN
in_PIN
the_DT
International_NN
Journal_NN
of_PIN
Neuropsychopharmacology_NN
,_,
Cattaneo_NN
's_POS
team_NN
focused_VBD
on_PIN
two_CD
biomarkers_NN
that_TSUB
measure_VPRT
blood_NN
inflammation_NOMZ
._.
Previous_JJ
studies_NN
have_VPRT [SPAU] [PEAS]
already_RB
linked_VBN
raised_VBN
levels_NN
of_PIN
inflammation_NOMZ
with_PIN
a_DT
poor_JJ
response_NN
to_PIN
antidepressants_NN
._.
The_DT
researchers_NN
measured_VBN
the_DT
two_CD
markers_NN
,_,
called_VBN
Macrophage_NN
Migration_NOMZ
Inhibitory_NN
Factor_NN
-LRB-_-LRB-
MIF_NN
-RRB-_-RRB-
and_ANDC
interleukin_NN
-LRB-_-LRB-
IL_NN
-RRB-_-RRB-
-1_CD
,_,
in_PIN
two_CD
groups_NN
of_PIN
depressed_JJ
patients_NN
before_IN
or_CC
after_IN
they_TPP3
took_VBD
a_DT
range_NN
of_PIN
commonly_RB
prescribed_VBN
antidepressants_NN
._.
They_TPP3
found_VBD [PRIV]
that_THVC
blood_NN
readings_GER
above_PLACE
a_DT
certain_JJ
threshold_NN
could_POMD [SPAU]
reliably_RB
predict_VB [PUBV]
the_DT
probability_NOMZ
of_PIN
a_DT
patient_JJ
responding_VBG
._.
Patients_NN
with_PIN
MIF_NN
and_CC
IL-1_JJ
levels_NN
above_PLACE
the_DT
thresholds_NN
had_VBD
a_DT
100_CD
%_NN
chance_NN
of_PIN
not_XX0
responding_VBG
to_PIN
conventional_JJ
,_,
commonly_RB
prescribed_VBN
antidepressants_NN
,_,
the_DT
researchers_NN
found_VBD [PRIV]
,_,
while_OSUB
those_DEMO
with_PIN
lower_JJ
levels_NN
did_EMPH
show_VB [PRIV]
a_DT
positive_JJ
treatment_NOMZ
response_NN
._.
Carmine_NN
Pariante_NN
,_,
a_DT
IoPPN_NN
professor_NN
who_WP [WHSUB]
worked_VBD
on_PIN
the_DT
team_NN
,_,
said_VBD [PUBV]
the_DT
results_NN
point_NN
to_PIN
a_DT
<sup>_JJ
~_CD
</sup>_JJ
clinically-suitable_JJ
approach_NN
for_PIN
personalising_VBG
antidepressant_JJ
therapy_NN
<sup>_NN
TM_NN
</sup>_NN
._.
